Evidence map›Paper›PMID 37869904›Full record

ReviewHypertension (Dallas, Tex. : 1979)2024

Kidney Intrinsic Mechanisms as Novel Targets in Renovascular Hypertension.

Alfonso Eirin, Alejandro R Chade, Lilach O Lerman

Open access · greenAbstract readReview
In one paragraph

Review in Hypertension (Dallas, Tex. : 1979), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Alfonso EirinDivision of Nephrology and Hypertension, Mayo Clinic, Rochester, MN (A.E., L.O.L.).ORCID 0000-0002-3864-9644
Alejandro R ChadeDepartment of Medical Pharmacology and Physiology, University of Missouri-Columbia (A.R.C.).ORCID 0000-0002-3672-3409
Lilach O LermanDivision of Nephrology and Hypertension, Mayo Clinic, Rochester, MN (A.E., L.O.L.).ORCID 0000-0002-3271-3887
Mayo Clinic · USUniversity of Missouri · US

Funding

Microcirculation in Renovascular HypertensionR01HL095638 · NHLBI · UNIVERSITY OF MISSOURI-COLUMBIA · PI CHADE, ALEJANDRO ROBERTO · 2010 to 2021
$3.9M
Obesity-induced dysfunction of human MSC in peripheral microvascular repairR01HL158691 · NHLBI · MAYO CLINIC ROCHESTER · PI Alfonso Eirin, Lilach O Lerman · 2022 to 2026
$3.4M
Obesity-induced mesenchymal stem cell senescenceR01DK120292 · NIDDK · MAYO CLINIC ROCHESTER · PI LERMAN, LILACH O · 2019 to 2022
$2.6M
Quantitative magnetization transfer MRI for evaluation of renal fibrosisR01DK122734 · NIDDK · MAYO CLINIC ROCHESTER · PI LERMAN, LILACH O · 2020 to 2023
$2.2M
Role of mitochondrial microRNAs (mitomiRs) in endogenous renal repairR01DK129240 · NIDDK · MAYO CLINIC ROCHESTER · PI Alfonso Eirin · 2023 to 2026
$1.8M
A new large pre-clinical model of aging-related heart failure: a platform to develop new therapies for HFpEFR21AG084154 · NIA · UNIVERSITY OF MISSOURI-COLUMBIA · PI CHADE, ALEJANDRO ROBERTO · 2023 to 2023
$460k
Noninvasive Evaluation of Renal Allograft Fibrosis by MRIR21AG062104 · NIA · MAYO CLINIC ROCHESTER · PI LERMAN, LILACH O · 2020 to 2021
$414k
Role of mitochondrial microRNAs (mitomiRs) in endogenous renal repairR56DK129240 · NIDDK · MAYO CLINIC ROCHESTER · PI EIRIN, ALFONSO · 2021 to 2021
$100k
NHLBI NIH HHS R01 HL095638NHLBI NIH HHS R01 HL158691NIA NIH HHS R21 AG062104NIA NIH HHS R21 AG084154NIDDK NIH HHS R01 DK120292NIDDK NIH HHS R01 DK122734NIDDK NIH HHS R01 DK129240NIDDK NIH HHS R56 DK129240
6 · The paper itself

Abstract

Almost a hundred years have passed since obstruction of the renal artery has been recognized to raise blood pressure. By now chronic renovascular disease (RVD) due to renal artery stenosis is recognized as a major source of renovascular hypertension and renal disease. In some patients, RVD unaccompanied by noteworthy renal dysfunction or blood pressure elevation may be incidentally identified during peripheral angiography. Nevertheless, in others, RVD might present as a progressive disease associated with diffuse atherosclerosis, leading to loss of renal function, renovascular hypertension, hemodynamic compromise, and a magnified risk for cardiovascular morbidity and mortality. Atherosclerotic RVD leads to renal atrophy, inflammation, and hypoxia but represents a potentially treatable cause of chronic renal failure because until severe fibrosis sets in the ischemic kidney, it retains a robust potential for vascular and tubular regeneration. This remarkable recovery capacity of the kidney begs for early diagnosis and treatment. However, accumulating evidence from both animal studies and randomized clinical trials has convincingly established the inadequate efficacy of renal artery revascularization to fully restore renal function or blood pressure control and has illuminated the potential of therapies targeted to the ischemic renal parenchyma to instigate renal regeneration. Some of the injurious mechanisms identified as potential therapeutic targets included oxidative stress, microvascular disease, inflammation, mitochondrial injury, and cellular senescence. This review recapitulates the intrinsic mechanisms that orchestrate renal damage and recovery in RVD and can be harnessed to introduce remedial opportunities.

Indexed as

AtherosclerosisHypertension, RenovascularRenal Artery ObstructionAnimalsChronic DiseaseHumansInflammationKidneyKidney Function Testshemodynamicsinflammationkidneymorbidityoxidative stress

Identifiers

PMID37869904
PMCPMC10842320
OpenAlexW4387865631

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.